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Abstract
Background: Ketamine ester analogs, SN 35210 and SN 35563, demonstrate different pharmacological profiles to
ketamine in animal models. Both confer hypnosis with predictably rapid offset yet, paradoxically, SN35563 induces a
prolonged anti-nociceptive state. To explore underlying mechanisms, broad transcriptome changes were measured
and compared across four relevant target regions of the rat brain.
Results: SN 35563 produced large-scale alteration of gene expression in the Basolateral Amygdala (BLA) and
Paraventricular Nucleus of the Thalamus (PVT), in excess of 10x that induced by ketamine and SN 35210. A smaller
and quantitatively similar number of gene changes were observed in the Insula (INS) and Nucleus Accumbens
(ACB) for all three agents. In the BLA and PVT, SN 35563 caused enrichment for gene pathways related to the
function and structure of glutamatergic synapses in respect to: release of neurotransmitter, configuration of
postsynaptic AMPA receptors, and the underlying cytoskeletal scaffolding and alignment.
Conclusion: The analgesic ketamine ester analog SN 35563 induces profound large-scale changes in gene
expression in key pain-related brain regions reflecting its unique prolonged pharmacodynamic profile.
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Background
For more than 50 years ketamine has been used as an an-
aesthetic drug with an unparalleled safety profile. Latterly,
ketamine’s identified analgesic and rapid-onset antidepres-
sant properties have been incorporated into clinical prac-
tice. Regrettably, a growing market as a recreational drug
of abuse is also apparent. Traditionally recognised as a
non-competitive N-methyl-D-aspartate (NMDA) receptor
antagonist, ketamine also binds with a broad range of
other neuronal transporters and receptors, including
opioid receptors, Dopamine D2 and monoamine trans-
porters, serotonergic and cholinergic signalling systems,
and non-NMDA glutamatergic receptors [1, 2]. Given
ketamine’s complex pharmacologic profile it is perhaps
unsurprising that the underlying mechanisms of its
myriad of pharmacodynamic effects are yet to be fully
elucidated.
Compared to ketamine, two recently developed
ketamine esters – SN 35210 (subsequently referred to as
R1) and SN 35563 (R5) – demonstrate a shorter recov-
ery time and absent psychotomimesis following hypnosis
[3]. In addition, it was shown that R5 treatment induced
a profound analgesic effect that extended to at least one
hour after the plasma level of the drug had completely
disappeared due to rapid hydrolysis by tissue esterases.
Because a related ketamine ester analogue with the same
primary metabolite showed no such antinociceptive ac-
tion, we are confident this analgesia is not mediated by
an active metabolite.
While it is long held that the primary mode of action of
ketamine is via the NMDA receptor, the drug also binds to
other targets, including olfactory [4], acetylcholine [5], and
pacemaker current (HCN1) [6] receptors, suggesting the
possibility also for alternative modes of action for analogs
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: gregory.jacobson@waikato.ac.nz
1Faculty of Science and Engineering, The University of Waikato, Hillcrest,
Hamilton 3216, New Zealand
Full list of author information is available at the end of the article
Jacobson et al. BMC Genomics          (2019) 20:281 
https://doi.org/10.1186/s12864-019-5649-6
of ketamine. One explanation for the mechanisms of pro-
longed analgesia exhibited by R5 is that it may induce key
changes in early gene expression. It is known that ketamine
and other NMDA receptor antagonists cause a variety
of changes in expression of a significant number of
genes [7, 8]. Therefore, we used mRNA sequencing to
quantify gene expression changes induced in four key
higher order pain-related regions of the rat brain by a 45
min infusion of ketamine and the related analogues. Based
on this large-scale transcriptome analysis, we were able to
define transcript classes most profoundly modified by each
compound in each of the four brain regions. We used Reac-
tome modelling in order to delineate potential intra- and
inter-neuronal pathways affected by these drugs.
Results
Behavioural metrics
Infusion of all study drugs produced hypnosis charac-
terised by Loss of Righting Reflex (LORR), and blunted re-
sponses to external stimuli. Dose to LORR was ketamine
27.9 (1.8) mg/kg, R1 55.1 (10.9) mg/kg, R5 77.1 (8.4) mg/
kg. Total drug dosing to 45min was ketamine 95.5mg/kg,
R1 229.8 (13.2) mg/kg, and R5 251.5 (9.3) mg/kg.
Transcript sequencing
An average of 4.3 gigabases of sequence data was pro-
duced from each sample and after filtering this produced
30.1 (+/− 0.34) mb (Mean; SD) of clean reads for each
sample. Processing by Cufflinks software produced a
total transcript list of 21,602 +/− 148 (mean +/− SD)
across the 16 samples, and this represents ~30X cover-
age (read number and data quality are included as Add-
itional file 1).
Differentially expressed genes
The lists of differentially expressed genes were sorted as
up- and down-regulated transcripts for each brain re-
gion. The highest numbers of differentially expressed
genes were found in the BLA and PVT from the
R5-treated animals. A summary of the differentially
expressed genes for each drug in different regions is
shown in Fig. 1 (with detailed gene information, False
Detection Rate [FDR] values, and fold change included
as Additional file 2). The genes in each subset in the
Venn diagrams in the figure are provided as another
supplementary file (Additional file 3). Furthermore pat-
terns of expression were confirmed for selected differen-
tially expressed genes using quantitative PCR (qPCR)
(Additional file 4).
Reactome analysis reveals largest network changes are
induced by R5 in BLA and PVT
There were no enrichments for either ketamine or R1
drugs in any of the four regions examined, but large
changes in the BLA and PVT in the R5-treated animals.
The up- and down-regulated Reactome enrichments are
summarised in Fig. 2. In some cases the same term ap-
pears as both up- and down-regulated and this reflects
subsets of the analysed genes falling into these different
grouping terms. The most prominent changes were seen
in cellular functions that controlled synaptic activity, es-
pecially glutamatergic synapses. When separated into
up- and down-regulated gene lists, the R5-induced
changes in the BLA were broadly opposite to the direc-
tion of changes seen in the PVT.
Interaction network analysis: features of R5-induced gene
networks
In agreement with the aforementioned Reactome ana-
lysis, the ketamine and R1 treatments did not result in
any enrichment for interactions in the examined regions.
In contrast, significant enrichment was seen for R5, as
shown in Table 1 (top 10 most enriched). A STRING
diagram shows the enriched terms for the BLA and PVT
with R5 treatment (Fig. 3).
It has been shown previously that for a given drug
treatment, the expression levels of the drug binding tar-
gets themselves are very unlikely to be altered [9]. In-
stead, networked proteins downstream to the target are
more likely to show dysregulated expression. Applying
this rationale, we identified significantly enriched inter-




Ketamine is well-known for its ability to induce a state
of dissociative anaesthesia and profound analgesia. Re-
ports of rapid-onset antidepressant action extending far
beyond the pharmacokinetic time course of the drug
have further increased clinical applications, as well as
stoking academic interest in the underlying mechanisms
of action for ketamine. The novel ketamine ester ana-
logues R1 and R5 have been developed from ketamine
with the specific goal of achieving fast offset hypnosis
and absent psychomimetic properties through rapid tis-
sue mediated hydrolysis to inactive metabolites. How-
ever, while both analogues confer accelerated arousal,
only R5 exhibits a prolonged anti-nociceptive action that
persists for up to 90 mins following cessation of drug
administration.
In the present experiment we utilise drug-induced
gene expression profiling to explore the disparate
neuro-behavioural effects of these drugs. In particular,
we were interested in the potential of R5 to induce iden-
tifiable transcriptome-level changes in dedicated
pain-related brain regions. In summary, we found that
the compounds all altered individual gene expression for
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about 50–100 genes in all the brain regions examined,
but in addition R5 profoundly altered the expression of
many more genes in specific brain regions.
Ketamine and R1 induced broadly comparable changes
both in terms of the number and scope of gene perturba-
tions. Literature reports of ketamine-induced gene alter-
ations in brain tissue demonstrate significant heterogeneity.
Ficek et al. [10] identified 52 gene transcripts (including for
Dusp1, Per1 and Fkbp5 genes) with altered expression in
mouse Striatum and Hippocampus following ketamine
administration. Functional linkage was reported with
mitogen-activated protein kinase (MAPK), Il-6, and insulin
signalling pathways with expression differing throughout
the eight hours sampling interval. In a study exploring the
role of ketamine and sleep deprivation in a mouse model
Orozco-Solis et al. 2017, have shown alterations in expres-
sion levels of 1149 genes in the Anterior Cingulate Cortex
using a threshold of p < 0.05 [8]. For the 64 transcripts that
were in both the sleep and ketamine datasets, the related
ontologic categories included entrainment of the circadian
clock, regulation of dentritic morphogenesis, ribosome
function, nucleic acid binding, and cellular metabolic pro-
cessing. Lack of commonality in reported gene alterations
following ketamine exposure likely reflect both dose and
time dependent factors in employed models, in addition to
variation in sites of brain sampling.
A
B
Fig. 1 (a) Venn diagrams showing the scale of differentially expressed gene (DEGs) changes in the different brain regions (ACB, BLA, INS and PVT)
examined; and (b) bar chart showing proportion of genes up- (green) and down-regulated (red) in each tissue
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In our work we have also observed significant variabil-
ity in ketamine-induced gene expression across the dif-
ferent interrogated brain regions. Indeed, of all
differentially expressed genes only 49 were commonly
expressed in two brain regions following ketamine treat-
ment, 29 in three brain regions, and eight (HSD17B11,
NCAPD3, SLITRK5, KCNG1, NUP205, NCAPD3,
SREK1, CYTH3) differentially expressed across all four
brain regions examined. Clearly, in addition to exposure
and sampling intervals, ketamine-induced transcriptome
signatures demonstrate significant regional variability.
In contrast, R5 altered expression in about ten times the
number of genes in regions of the brain linked to high-level
analgesia networks – the BLA and PVT [11–15]. This was
supported by the gene transcription network analyses,
which showed no significant enrichment in ketamine and
R1 animals. The main effects of R5 were on the expression
of various genes controlling the function and structure of
glutamatergic synapses; both as regards release of neuro-
transmitter, configuration of postsynaptic AMPA receptor,
and the underlying cytoskeletal scaffolding and alignment.
R5 analog causes alterations in postsynaptic density-
associated gene networks
In animals treated with R5, in the BLA and PVT there was
a strong enrichment for interactions associated with post-
synaptic density Discs Large MAGUK Scaffold Protein 4
(PSD95), which is encoded by the DLG4 gene and has a
central role in NMDAR trafficking, membrane-targeting
and internalization [16]. YWHAZ is involved in the
A
B
Fig. 2 Reactome data from all differentially expressed genes in the 1% gene list from R5-treated animals for (a) BLA and (b) PVT by p value of
enriched Reactome term. Upregulated enriched terms are in green while downregulated are in red
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regulation of actin filament dynamics and is differentially
expressed after glutamate exposure in hippocampal slice
cultures [17]. SHANK3 is involved in NMDA receptor teth-
ering and dendritic spine rearrangement and has been iden-
tified as a regulator of the anti-depressive properties of
ketamine [18].
These proteins are components of the postsynaptic
density network that connects many membrane proteins,
including the excitatory neurotransmitter receptors
NMDA, AMPA and mGlut, to the actin cytoskeleton.
The association of ketamine with dysregulation of genes
involved in postsynaptic density has been reported previ-
ously [19–21]; and Yang and colleagues [22] observed
increased dendritic filopodia after 4 h of anaesthesia with
ketamine-xylazine. Furthermore, the anaesthetic effect of
halothane is enhanced in mice following disruption to
PSD95-PDZ2 with intraperitoneal injection of a
Tat-PSD95-PDZ2 fusion protein [23]. These studies
highlight that cytoskeletal protein networks represent a
novel anaesthetic target, disruption of which could have
functional implications. Changes in the expression of
scaffolding protein components of this network are asso-
ciated with synaptic plasticity through regulation of
receptor localisation and distribution [24], and interac-
tions between PSD95 and NMDR subunits GRIN1 and
GRIN2, and between PSD93 and AMPAR are particu-
larly important [25]. The postsynaptic density network
also mediates the efficiency of neurotransmission pos-
sibly through arrangement of so-called ‘nanocolumns’,
aligning pre-synaptic neuron regions rich in secreted
neurotransmitter-containing vesicles with the receptors
of the postsynaptic neuron [26].
There is also accumulating evidence of the importance
of AMPA receptors in analgesic mechanisms associated
with anaesthetic and non-anaesthetic drugs – such as
xenon [27], halothane [28], and the AMPA antagonist
Tezampel [29]. The amygdala is known to be associated
with the emotional component of the pain experience
[30, 31], and is linked with the paraventricular thalamus
[32] in a circuit that modulates the endogenous descend-
ing anti-nociceptive pathways [33]. Even within the
amygdala itself, there are intricately linked excitatory
and inhibitory modules. Clearly the mechanistic details
of how R5 alters the balance will require specific future
experiments.
Lisek et al. [21] studied the effects of ketamine on
psychosis and showed that ketamine increases synaptic
glutamate release in the cortex and striatum. This was
associated with an increased expression of glutamate
transporters, VGLUT1 (SLC17A7) and VGLUT2
(SLC17A6), and a decreased expression of membrane
glutamate reuptake pump excitatory amino acid trans-
porter 2 (EAAT2) (a.k.a. solute carrier family 1 member
2: SLC1A2). In our experiment, no differential expres-
sion in these genes was seen with ketamine treatment in
any tissue. However, in R5-treated animals, contrary
changes in VGLUT gene expression were seen in the
BLA (VGLUT1 down; VGLUT2 up) and PVT (VGLUT1
up; VGLUT2 down). Neither region however showed
changes in EAAT2/SLC1A2 expression. There is a possi-
bility that these differences may explain some pharmaco-
dynamic features of R5, such as reduced behavioural
changes consistent with diminished post-anaesthetic
psychosis (Harvey, unpublished observations).
Conclusion
We have demonstrated, using transcriptomic analysis
with various bioinformatics tools, that the antinocicep-
tive action of R5 is associated with large-scale early tran-
scriptome changes in the key pain-related brain regions,
the BLA and PVT. Predominance of dysregulated gluta-
minergic signalling machinery suggests that it may serve
as a functionally relevant binding target in R5-mediated
Table 1 Enrichment of differentially expressed genes (DEGs) for
known interactions (“interactome”) for each region and drug
combination. The most enriched (up to 10) are shown for each
brain region/drug combination
Region # interactions (p < 0.5) Top interactions p value














INS 1 NTRK1 interactions 9.35E-07










Jacobson et al. BMC Genomics          (2019) 20:281 Page 5 of 10
analgesia. These will be explored later for relevance in
the novel effects of the analogues such as prolonged an-
algesia and memory effects on pain perception.
Methods
Drugs and animals
Ketamine (Hospira Australia Ltd., VIC, Australia) was
sourced from a commercial supplier. Ketamine analogues
R1 and R5 (R1: SN35210 = racemic methyl 4-((1-(2-chloro-
phenyl)-2-oxocyclohexyl)amino)pentanoate hydrochloride
and R5: SN35563 = racemic isopropyl 3-((1-(2-chlorophe-
nyl)-2-oxocyclohexyl)amino)propanoatehydrochloride were
synthesized according to a previously reported procedure
[3] by the Auckland Cancer Society Research Centre La-
boratory (University of Auckland, New Zealand).
Ethical approval for animal experimentation was ob-
tained from the University of Waikato Animal Ethics
Committee (University of Waikato, Hamilton, New Zea-
land). Adult female Sprague-Dawley rats (280–370 g) ob-
tained from breeding stock from the University of
Waikato small animal unit were randomised (random
number generation) into four groups of five animals for
the experiments. Rats, housed in standard Plexiglas
cages under constant temperature (21 °C) and a 12:12
light/dark cycle (lights on at 07:00), were allowed ad libi-
tum access to standard laboratory chow and tap water
until the day of the experiment. All experiments were
conducted during the first half of the light phase.
Drug treatments
Sedative infusions (defined by continuous Loss of Righting
Reflex [LORR]) for ketamine, R1 and R5, and negative
control were undertaken following venous cannulation of
the marginal tail vein. Ketamine-treated animals (n = 5)
received intravenous ketamine (10mg/mL) initially at 20
mg/kg/min until LORR, and thereafter at 2mg/kg/min to
45 mins. R1-treated animals (n = 5) received intravenous
SN 35210 (10mg/mL) initially at 20mg/kg/min until
LORR, and thereafter at 4mg/kg/min to 45 mins.
R5-treated animals (n = 5) received intravenous SN 35563
(10mg/mL) initially at 20mg/kg/min until LORR, and
thereafter at 4 mg/kg/min to 45 mins. Control animals
(n = 5) received continuous infusion of 0.9% saline so-
lution at 0.4 mL/kg/min for 45 mins.
Tissue collection and RNA isolation
After 45 mins, drug infusions were halted and animals
immediately euthanized by decapitation. Brains were
dissected and the Nucleus Accumbens (ACB), Basolat-
eral Amygdala (BLA), Paraventricular nucleus of the
Thalamus (PVT) and Insula (INS) collected based on
the coordinates from the Paxinos and Watson brain
atlas. The tissue from each region was divided in a bilat-
eral fashion, i.e., one side was placed into one tube as a
pooled sample for each treatment group and the other
side placed in separate tubes corresponding to a given
brain site in each individual animal. The tubes contained
A B
Fig. 3 Combined STRING graphic of all enriched interactions for R5 in: (a) BLA and (b) PVT. Up- and down-regulated gene lists were combined.
Each node represents genes whose expression levels were altered by treatment with R5. Links between nodes represent the strength of
association between gene changes
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RNAlater™ (Thermo Fisher Scientific, NZ). After over-
night incubation at 4 °C in RNAlater, the samples were
frozen at − 20 °C. The pooled samples (consisting of 16
tubes - control and three different drug treatments -
namely ketamine, R1 or R5 - for each of four brain re-
gions) were submitted for transcriptome sequencing
(BGI, Shenzhen, Guangdong, China). For longer term
storage the tubes containing ACB, BLA and INS of each
individual animal were stored in RNAlater™ at − 80 °C
for later qPCR analysis.
Next generation sequencing, filtering and mapping
The processing and analysis in this and the next section
(splicing variation analysis) were carried out by a com-
mercial service (BGI, Shenzhen, Guangdong, China).
Briefly, total RNA was extracted from the pooled brain
tissue for each region and mRNA enriched using Oli-
go(dT) magnetic beads. cDNA was made using random
hexamers, a size selection performed and amplification
carried out by a PCR step. Transcriptome sequencing
and basic filtering was on an Illumina Hiseq platform.
After sequencing, reads of low-quality, containing
adaptor sequences and those with a high content of un-
known bases, were removed. Read data from each sam-
ple were mapped to a reference genome using a
bioinformatic approach including Stringtie [34] to recon-
struct transcripts and the Cuffcompare module of Cuf-
flinks [35]. Novel transcripts were merged with
reference transcript sequences and clean reads mapped
using Bowtie2 [36]. Then gene expression level was de-
termined using RSEM [37].
Data interpretation and bioinformatics
In this study we applied a number of tools to gain
insight into the functional significance of the expression
data. In the first instance, genes that showed a greater
than a two-fold change in drug-treated vs. control ani-
mals, and were also included in the top 1% as ranked by
FDR level, were classified as differentially expressed
genes (giving a final FDR cut-off of p < 0.0005). This is
obviously a conservative classification, aimed to reduce
the chance of random changes in gene expression being
falsely attributed to a drug effect. Because of the low
Fig. 4 Independent and shared interaction terms for R5 in BLA and PVT regions for terms enriched in Interactome analysis, but not showing
differential expression in response to drug treatments
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power, we have probably underestimated the actual drug
effects on gene expression.
Subsequently, the question arose as to whether the
changes in gene expression were occurring in isolated
genes, or whether there was a consistent pattern of al-
tered gene expression linked to certain functional path-
ways within a cell. The latter implies greater functional
impact. Therefore, the list of differentially expressed
genes was queried against public databases of known
gene/protein cellular functions to reveal whether the list
had over-representation (was enriched) for associations
with a particular functional term, e.g. “transmission
across chemical synapses”. Two databases were interro-
gated, namely the Reactome and the Interactome.
Reactome
The Reactome is a curated database that summarizes
both gene- and protein- functional associations. Reac-
tome analysis was carried out by searching gene lists
using rat genome database IDs corresponding to each
condition and brain region using the Panther ontol-
ogy database [38] (with Bonferroni FDR applied). This
produced an output of Reactome terms that were
enriched in the lists. These same enrichments were
also visualised using gene symbol annotations at the
Reactome database [39].
Interaction/interactome analysis
The Interactome is the collection of all known and pub-
licly available protein-protein associations for the proteins
that would be produced from a submitted list of genes.
‘Interaction analysis’ thereby is a test of whether a particu-
lar gene list has significantly more terms associated with a
particular known functional cellular interaction than
would be expected by chance. Differentially expressed
genes were searched by gene symbol using the TOPP-
GENE database [40]. All interactions with a FDR < 0.05
from the 1% of 0.05 FDR gene lists were considered. To
produce the short list of possible binding targets for the
drugs, we applied a previously described approach that as-
sumes that gene expression of drug target proteins is not
likely to be altered by treatment with that drug [9]. Our
approach differed slightly in that we did not include
Search Tool for InteracTions of CHemicals (STITCH)
[41] database analysis as that database has no data on the
analogue drugs. The interaction terms were filtered using
this prediction of no change in expression of actual tar-
gets. The highest scoring enriched networks for each brain
region/drug combination from this filtered list were pro-
filed using the STRING database [42]. For STRING, all
terms for each region were clustered by Markov Cluster
Algorithm clustering (MCL) by inflation parameter of 6
with confidence setting at 0.4 (medium).
Table 2 Known functions of candidate R5 target proteins (“common” list). Descriptions are from UniProt database (www.uniprot.org)
Common terms Description
CACNA1A
Calcium Voltage-Gated Channel Subunit Alpha1 A
Voltage-sensitive calcium channel involved in neurotransmitter release
GRIP1
Glutamate Receptor Interacting Protein 1
Scaffold for multi-protein signalling complexes and mediator of trafficking of its binding partners,
related to glutamate receptors.
DLG4
Discs Large MAGUK Scaffold Protein 4
Guanylate kinase (MAGUK) family member. Mediator of post-synaptic events; including plasticity
via by interaction with cytoplasmic tail of NMDA receptor (NMDR), DLG2 and shaker type
potassium channels following ligand binding.
GRIN1
Glutamate Ionotropic Receptor NMDA Type Subunit
1
NMDA receptor subunit associated with synaptic plasticity
GNAI1
Guanine Nucleotide-Binding Protein G(I) Subunit
Alpha-1
Signal transduction downstream of G-protein coupled receptor
DGUOK
Deoxyguanosine Kinase
Nucleoside kinase activity in mitochondria
KALRN
Kalirin RhoGEF Kinase
Signal transduction of pathways for neuronal shape, growth and plasticity mainly via effects on
actin cytoskeleton
GRIN2A
Glutamate Ionotropic Receptor NMDA Type Subunit
2A
NMDA receptor subunit associated with long-term potentiation and efficiency of transmission
SHANK3
SH3 And Multiple Ankyrin Repeat Domains 3.
Scaffold protein between membrane proteins and cytoskeleton. Involved in signal transduction
YWHAZ
Tyrosine 3-Monooxygenase/Tryptophan 5-
Monooxygenase Activation Protein Zeta
Regulation of many signalling pathways via binding to phosphoserine containing proteins
CALM1
Calmodulin 1
Involved in control of function of many proteins and calcium-dependent inactivation of
CACNA1C
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Additional file 1: QC sequencing. Quality control and summary statistics
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Additional file 2: Detailed gene lists. Excel spreadsheet with worksheets
showing all differentially expressed genes found in each sample and
within the false detection rate cut-off used. (XLSX 591 kb)
Additional file 3: DEGs in Venn diagram. Lists of DEGs found in all Venn
diagram subsets, showing unique and shared genes between control
(vehicle) and drug treatments. (XLSX 89 kb)
Additional file 4: qPCR data. qPCR data for tested changes in gene
expression. (DOCX 13 kb)
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